Recombinant Mouse IFN-zeta/Limitin Protein(HEK293), C-6*His

IFN-zeta, also known as Limitin, is a member of the interferon (IFN) family, which plays a critical role in the immune response against viral infections and tumors. It is produced primarily by immune cells and has been shown to exhibit antiproliferative and antiviral activities. Research on IFN-zeta has gained momentum due to its unique properties that differ from other IFNs, such as IFN-alpha and IFN-beta. These properties include the ability to enhance the activity of natural killer (NK) cells and modulate the immune response. Recent studies have indicated that IFN-zeta could be a key player in combating chronic viral infections and certain malignancies, as it not only triggers the immune system but also poses less risk of adverse side effects compared to other IFNs. The recombinant protein form of IFN-zeta is of particular interest for therapeutic applications, as it offers the potential to harness its immune-modulating effects in a controlled manner. Additionally, ongoing research aims to elucidate the signaling pathways activated by IFN-zeta, as well as its interactions with other cytokines and immune cells. Understanding the mechanisms underlying IFN-zeta's actions can pave the way for the development of novel immunotherapies that exploit its unique characteristics, particularly for conditions where conventional treatments are lacking efficacy. Thus, the study of IFN-zeta and its recombinant protein form is essential for advancing therapeutic strategies in infectious diseases and cancer, providing hope for improved clinical outcomes.